Clinical Trial

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Name: Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) — clinical trial record (NCT06670222)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).

Protocol Amendment History 1 change

notable Primary completion pushed: 2026-07 -> 2026-08-24 2026-08-07

Trial Details

NCT Number	NCT06670222
Lead Sponsor	Groupe Francophone des Myelodysplasies
Conditions	Low-risk Myelodysplastic Syndromes
Enrollment	24 participants
Start Date	2025-07-22
Primary Completion	2026-08-24 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-06